Brl 32872 | CAS#113241-47-7

MedKoo Cat#: 535079 | Name: Brl 32872

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brl 32872 is a bioactive chemical.

Chemical Structure

Brl 32872

CAS#113241-47-7

Theoretical Analysis

MedKoo Cat#: 535079

Name: Brl 32872

CAS#: 113241-47-7

Chemical Formula: C29H36ClN3O7

Exact Mass: 573.2242

Molecular Weight: 574.07

Elemental Analysis: C, 60.68; H, 6.32; Cl, 6.18; N, 7.32; O, 19.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Brl 32872; Brl-32872; Brl32872

IUPAC/Chemical Name

Benzamide, N-(3,4-dimethoxyphenyl)-N-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-4-nitro-, monohydrochloride

InChi Key

CMKVOHIRMCFVBJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C29H35N3O7.ClH/c1-30(18-15-21-7-13-25(36-2)27(19-21)38-4)16-6-17-31(24-12-14-26(37-3)28(20-24)39-5)29(33)22-8-10-23(11-9-22)32(34)35;/h7-14,19-20H,6,15-18H2,1-5H3;1H

SMILES Code

O=C(N(C1=CC=C(OC)C(OC)=C1)CCCN(CCC2=CC=C(OC)C(OC)=C2)C)C3=CC=C([N+]([O-])=O)C=C3.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 574.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J. High- affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther. 2001 May;297(2):753-61. PMID: 11303067. 2: Faivre JF, Forest MC, Gout B, Bril A. Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscle. Effect on early after-depolarizations and repolarization dispersion. Eur J Pharmacol. 1999 Oct 27;383(2):215-22. doi: 10.1016/s0014-2999(99)00614-7. PMID: 10585537. 3: Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR Jr. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther. 1996 Feb;276(2):637-46. PMID: 8632331. 4: Gout B, Nichols AJ, Feuerstein GZ, Bril A. Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia. J Cardiovasc Pharmacol. 1995 Oct;26(4):636-44. doi: 10.1097/00005344-199510000-00020. PMID: 8569227. 5: Karle CA, Thomas D, Kiehn J. The antiarrhythmic drug BRL-32872. Cardiovasc Drug Rev. 2002 Summer;20(2):111-20. doi: 10.1111/j.1527-3466.2002.tb00186.x. PMID: 12177689. 6: Bril A, Forest MC, Cheval B, Faivre JF. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. Cardiovasc Res. 1998 Jan;37(1):130-40. doi: 10.1016/s0008-6363(97)00216-2. PMID: 9539867. 7: Bril A, Faivre JF, Forest MC, Cheval B, Gout B, Linée P, Ruffolo RR Jr, Poyser RH. Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations. J Pharmacol Exp Ther. 1995 Jun;273(3):1264-72. PMID: 7791099. 8: Lee K, Park JY, Ryu PD, Kwon LS, Kim HY. IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23. doi: 10.2174/1568016033477414. PMID: 15326913. 9: Faivre JF, Rouanet S, Bril A. Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 1998 Apr;31(4):551-7. doi: 10.1097/00005344-199804000-00013. PMID: 9554804. 10: Kalifa J, Bernard M, Gout B, Bril A, Cozma D, Laurent P, Chalvidan T, Deharo JC, Djiane P, Cozzone P, Maixent JM. Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch- related atrial fibrillation. Cardiovasc Drugs Ther. 2007 Feb;21(1):47-53. doi: 10.1007/s10557-007-6001-y. Epub 2007 Mar 14. PMID: 17356910. 11: Nadler G, Faivre JF, Forest MC, Cheval B, Martin M, Souchet M, Gout B, Bril A. Synthesis, electrophysiological properties and analysis of structural requirements of a novel class of antiarrhythmic agents with potassium and calcium channel blocking properties. Bioorg Med Chem. 1998 Nov;6(11):1993-2011. doi: 10.1016/s0968-0896(98)00166-7. PMID: 9881092.